528 results about "Treatment protocol" patented technology

A thin film electroluminescent (TFEL) phototherapy device based on high field electroluminescence (HFEL) or from organic light emitting devices (OLED), consistent with certain embodiments of the present invention has a battery and a charging circuit coupled to the battery, so that when connected to a source of current acts to charge the battery. A TFEL panel produces light when voltage from the power source (battery or AC source) is applied. A processor such as a microprocessor is used to control the application of voltage from the power source to the TFEL panel under control of a control program. A housing is used to contain the battery, the charging circuit and the processor and carry the TFEL panel on an outer surface thereof. In one embodiment, the housing incorporates a removable cover that uncovers a household electrical plug useful for supplying charging current to the charger. In use, a method of carrying out phototherapy, consistent with certain embodiments of the invention involves diagnosing a condition of an affected area of tissue that can be treated with phototherapy. A treatment protocol is determined including, for example, a treatment light intensity, a treatment time, a light modulation characteristic and a treatment light wavelength suitable for treating the condition. The affected area is then irradiated with light from the TFEL panel in accord with the treatment protocol.

An online occupational medicine management system and method that allow authorized physicians, patients, employers, and insurance companies to capture, store, retrieve, and disseminate an employee's medical records from any computer having Internet access. The employee medical information can be shared between the aforementioned parties in real time, resulting in improved quality of care and greater efficiency in the field of work-related injuries, i.e., workers' compensation. The online occupational medicine management system also provides physicians with diagnosis appropriate treatment protocols that can be pre-approved by a patient's employer and/or the employer's insurance company, thus requiring monitoring only of medical treatments that fall outside of the pre-approved protocols. Accordingly, administrative costs to insurance companies and employers are lessened, and payment time to physicians is reduced.

A vascular access device and method of using is disclosed. The vascular access device includes a housing defining a cavity and adapted to connect to a catheter. A self-sealing injection port and a subhousing are also provided. The subhousing may be movably connected to the housing so that a position of the other end of the subhousing relative to the housing can be selectively adjusted within a range of positions. A unidirectional fluid valve permits solution flow from the subhousing to the housing. The vascular access device may be utilized in a variety of treatment protocols including medication administration, fluid sampling, and placement of balloon catheters or guide wire-based medical devices.

A systems biology approach is used to characterize and relate the intestinal (gut) microbiome of a host organism (e.g. a human) to physiological processes within the host. Information regarding the types and relative amounts of gut microflora is correlated with physiological processes indicative of e.g., a patient's risk of developing a disease or condition, likelihood of responding to a particular treatment, for adjusting treatment protocols, etc. The information is also used to identify novel suitable therapeutic targets and/or to develop and monitor the outcome of therapeutic treatments. An exemplary disease/condition is the development of hepatic encephalopathy (HE), particularly in patients with liver cirrhosis.

A System manages IV pumps so that clinicians automatically receive alerts, decisions, and actions required to maintain a patient IV medication therapy according to a prescribed treatment protocol. An infusion pump monitoring system, includes an acquisition processor for acquiring fluid infusion parameters comprising a patient identifier, infusion fluid identifier and a rate of fluid infusion, for administration of an infusion fluid to a patient at a point of care using an infusion pump. The system also includes a repository of patient medical record information. A fluid infusion monitor uses acquired fluid infusion parameters for automatically searching a patient medical record in the repository for information concerning rate of fluid infusion of a particular infusion fluid and determining if a rate of a previously administered dose of the particular infusion fluid was lower than a rate indicated in the fluid infusion parameters. An interface processor automatically initiates generation of a message indicating a potential adverse reaction to the particular infusion fluid in response to a determination of a lower rate being employed for previously administering the particular infusion fluid.

An apparatus provides automatically controlled facial rejuvenation treatments and is comprised of a scanner for scanning a patient's face, a treatment robot, including a plurality of dermatological devices for treatment of facial skin, and a computer coupled to the scanner and robot for determining a treatment protocol of the patient's face based on a scanned input of the patient's face and for generating a plurality of commands for the treatment robot for movement and/or control of the plurality of dermatological devices for the automated treatment of the skin of the patient's face. A dermatological laser, needle injector, and/or air injector are used. The needle injector injects a minute amount of substance at a multiplicity of points within a computer-identified treatment area on the patient's face.

The present specification discloses systems and methods for patient monitoring using a multitude of display regions, at least two of which have the capability to simultaneously display real time patient waveforms and vital statistics as well as provide display for local and remote software applications. In one example, a primary display shows real time patient waveforms and vital statistics while a customizable secondary display shows trends, cumulative data, laboratory and radiology reports, protocols, and similar clinical information. Additionally, the secondary display can launch local and remote applications such as entertainment software, Internet and email programs, patient education software, and video conferencing applications. The dual display allows caregivers to simultaneously view real time patient vitals and aggregated data or therapy protocols, thereby increasing hospital personnel efficiency and improving treatment, while not compromising the display of critical alarms or other data.

A system for remote ischemic preconditioning that includes a cuff, and actuator, and a controller that operates the actuator according to a treatment protocol. The treatment protocol includes a plurality of treatment cycles that each comprise cuff actuation, an ischemic duration, cuff release, and a reperfusion duration.

A generic treatment protocol is disclosed for therapeutically treating a patient via an implantable treatment device. Treatment steps can be defined to start and end at absolute times, or can be programmed via telemetry to start a certain amount of time after termination of a previously executed treatment step. Treatment steps have a treatment rate or dose attribute and a duration attribute. Treatment steps may optionally enable patient-activated bolus overlays. Patient-activated rate or dosage adjustments can also optionally be enabled. Repeated-execution treatment-step groups are also provided. Such treatment-step groups can have start and end times, a group duration, and a group total dose, each defined in a manner similar to that for a treatment step. Treatment-step groups include a repetition count, which could be set to a value that causes the group to repeat forever. Single execution treatment steps can, accordingly, be programmed to execute before and/or after a repeated-execution treatment-step group.

A compliance/adherence management and automated data collection system uses a plurality of communications modalities implemented over wireless or wired communications systems for redundantly and persistently transmitting messages to and/or receiving messages from an end user for managing compliance/adherence of the end user concerning schedules and medication and treatment protocols. The system also uses wireless or wired communications modalities for automating real time collection of information from the end user concerning, for example, compliance with the schedule and/or protocol. The collected data can be remotely accessed, in real time, to monitor compliance/adherence and an end user's experiences resulting from compliance/adherence. Further, the management messages are so designed as to be highly personalized in order to achieve a more favorable response from the end user.

A method for dispensing alternative prescription products to a patient to provide the patient alternative treatment options and increase treatment protocol compliance. After a patient is diagnosed with a medical condition requiring treatment with a prescription product, the patient is provided with a kit containing a multiple continuous positive airway CPAP interfaces designed to adapt to a plurality of different facial features. Instead of being custom fitted by a CPAP interface specialist, the patient is given multiple CPAP interfaces to try and select the CPAP interface most desirable to the patient. The patient indicates the most desirable CPAP interface and, after a predetermined period of time, the patient is provided with a new CPAP interface matching the most desirable CPAP interface selected by the patient.

A method for treating a target tissue in a patient in need thereof is provided. The method includes the steps of identifying one or more characteristics of one or more cells of a target tissue; calculating a threshold electric field for inducing IRE in the target tissue based on the one or more characteristics; constructing a treatment protocol of one or more pulse parameters, wherein the treatment protocol is capable of inducing IRE in the target tissue; and delivering the treatment protocol to the target tissue. Systems for treatment planning for medical therapies involving administering electrical treatment energy are also provided.

The endometriosis treatment protocol provides for administering to a female patient in need of treatment for endometriosis a pharmaceutical composition in a form suitable for vaginal or rectal delivery having a pharmaceutically effective amount of an aromatase inhibitor, which may be either a steroid or non-steroidal. The pharmaceutical composition may be formed as a vaginal suppository, a rectal suppository, a vaginal gel, a rectal gel, a vaginal cream or a rectal cream. The pharmaceutical composition may optionally have pharmaceutically effective amounts of progesterone and calcitriol, and may be administered in combination with an oral COX-2 inhibitor. Alternatively, the pharmaceutical composition comprises an aromatase inhibitor administered vaginally or rectally and is administered in combination with oral calcitriol and the oral COX-2 inhibitor. The aromatase inhibitor is either steroidal or non-steroidal.

The Body Cavity Cancer Treatment Apparatus generates the magnetic field for use in a combined “Low Temperature Hyperthermia” and ionizing radiation and/or chemotherapy cancer treatment protocol. Unlike other competing systems, the Body Cavity Cancer Treatment Apparatus does not directly kill or ablate the cancer cells with killing temperatures rather, the Body Cavity Cancer Treatment Apparatus stresses the cancer and cancer stem cells by keeping them at a nominal 42° Celsius for some period of time via the heating of nano-particles that have been infused into the bladder, using the generated magnetic field.

The subject invention is directed to new and useful neurostimulation systems that include an implantable pulse generator dimensioned and configured for implantation in the skull of a patient. The implantable pulse generator has an electrode operatively associated with a distal end portion thereof and can be provided with adjustment means, such as an adjustable biasing member or spring arranged between the electrode to the distal end portion of the pulse generator. The subject invention is also directed to systems involving networked neurostimulators that are configured and adapted to work jointly in accordance with prescribed treatment protocol to effect a desired recovery from brain injury. Such networked neurostimulation systems are particularly advantageous for effecting relatively large and/or relatively distant regions of the brain. The subject invention is further directed to systems and methods for motor-evoked potential (MEP)-based neuromodulation. Further, AC and/or DC stimulation can be utilized, depending on the precise implementation.

Device for the controlled administration of substances to be inserted in a body cavity, characterized by: an anchoring medium allowing for a firm anchorage of the device in said body cavity; at least one substance support medium for the release of at least one substance into the body cavity following a specific protocol and in which each substance to be administered comprises an independent protocol that establishes a release kinetics with one or more substance administration stages, being each stage defined by a different release kinetics. These devices are useful to develop a simple or complex treatment protocol in mammals. The formulations applicable to the substance support media as well as the appropriate manufacturing processes are also provided.

Systems and methods are provided for modeling and for providing a graphical representation of tissue heating and electric field distributions for medical treatment devices that apply electrical treatment energy through one or a plurality of electrodes. In embodiments, methods comprise: providing one or more parameters of a treatment protocol for delivering one or more electrical pulses to tissue through a plurality of electrodes; modeling electric and heat distribution in the tissue based on the parameters; and displaying a graphical representation of the modeled electric and heat distribution. In another embodiment, a treatment planning module is adapted to generate an estimated target ablation zone based on a combination of one or more parameters for an irreversible electroporation protocol and one or more tissue-specific conductivity parameters.